Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Stomach Neoplasms 2 Vomiting 1 Squamous Cell Carcinoma of Head and Neck 1 Postoperative Nausea and Vomiting 1 Multiple Myeloma 1 Lymphoma 1 Carcinoma 1 Breast Carcinoma In Situ 1 Adenocarcinoma, Mucinous 1

Interventions

Cyclophosphamide 297 Rituximab 272 Etoposide 149 Filgrastim 142 fludarabine phosphate 120 Cytarabine 109 Vincristine 107 Melphalan 102 Radiotherapy 101 Doxorubicin 97 Peripheral Blood Stem Cell Transplantation 93 Methotrexate 91 fludarabine 86 Prednisone 86 Busulfan 86 Tacrolimus 66 Mycophenolic Acid 62 Granulocyte Colony-Stimulating Factor 60 Antilymphocyte Serum 58 Dexamethasone 57 Whole-Body Irradiation 55 Carmustine 54 Bortezomib 45 Cyclosporine 44 Lenalidomide 41 Methylprednisolone 40 sargramostim 39 Bendamustine Hydrochloride 37 ibritumomab tiuxetan 34 Ifosfamide 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma × Famotidine × Clear all

NCT03647072 2018-08-27

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Tanta University

Phase 3 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡